Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 1052
115th Congress(2017-2018)
BENEFIT Act of 2017
Active
Active
Passed Senate on Aug 3, 2017
Overview
Text
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
S. 1052 (Referred-in-House)


115th CONGRESS
1st Session
S. 1052

IN THE HOUSE OF REPRESENTATIVES

August 4, 2017

Referred to the Committee on Energy and Commerce

AN ACT

To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017” or the “BENEFIT Act of 2017”.

SEC. 2. Strengthening the use patient-experience data within benefit-risk framework.

Section 569C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–8c) is amended—

(1) in subsection (a)(1)—

(A) in subparagraph (A), by striking “; and” and inserting a semicolon;

(B) in subparagraph (B), by striking the period and inserting “; and”; and

(C) by adding at the end the following:

“(C) as part of the risk-benefit assessment framework in the new drug approval process described in section 505(d), considering relevant patient-focused drug development data, such as data from patient preference studies (benefit-risk), patient reported outcome data, or patient experience data, developed by the sponsor of an application or another party.”; and

(2) in subsection (b)(1). by inserting “, including a description of how such data and information were considered in the risk benefit assessment described in section 505(d)” before the period.

Passed the Senate August 3, 2017.

    Attest:julie e. adams,   
    Secretary